Higher expression of IL-32 was found to be associated with more proliferative and progression in the following cancers, AML, cutaneous T-cell lymphoma (CTCL), gastric B-cell lymphoma (GBCL), multiple myeloma (MM), HCC, and breast, lung, colon, pancreatic, gastric, and esophageal cancers (5–12, 22–25). Here, IL32 is linked to hepatocellular carcinoma.